



Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/510,876
				Filing Date	June 20, 2005
				First Named Inventor	Christine Power
				Art Unit	1647
				Examiner Name	R. M. Deberry
Sheet	1	of	1	Attorney Docket Number	SLII-P01-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C26	Auerbach, R., "Angiogenesis Assays: Problems and Pitfalls", Cancer and Metastasis Review, 19: pp 167-172, 2000.	
	C27	Berendsen, HJC, "A Glimpse of the Holy Grail", Science, 282: 642-643, 1998.	
	C28	Cancer Introduction from Merck manual accessed 6/26/07	
	C29	Clinical Aspects of Cancer from Merck Manual Accessed 6/26/2007.	
	C30	Designing Custom Peptides from SIGMA accessed 12/16/2004.	
	C31	Gastrointestinal Stromal Tumors from Merck Manual Accessed 2/25/2008.	
	C32	Gura T., "Cancer Models: Systems for Identifying New Drugs Are Often Faulty", Science, 278(5340): 1041-1042, enclosed pp. 1-6, 1997.	
	C33	Jain, RK., "Barriers to Drug Delivery in Solid Tumors", Scientific American, pp. 58-65, 1994	
	C34	Rudinger, J. "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence", JA Parsons Ed., pp. 1-7, 1976.	
	C35	Stomach Cancer from Merck Manual Accessed 2/25/2008.	
	C36	Voet and Voet, "Biochemistry", Second Edition, John Wiley & Sons, Inc., pp. 235-241, 1995.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.